Abstract
Severe and difficult-to-treat asthma patients have impaired health status and account for over half of the cost of the disease and probably all of its mortality. Guideline-based treatment for these refractory asthma patients includes high doses of inhaled steroids and long acting beta2-agonists (LABA) as well as additional medication such as theophylline, oral steroids and leukotriene-antagonists. However, management regimens are rarely successful in these patients, the treating physicians are often at a loss and there are still many areas of uncertainty regarding steroid-responsiveness, safety issues and maximal dosing of inhaled corticosteroids (ICS) and bronchodilators and possible differences between ICS preparations. Furthermore, there are many other classes of medication that have been or are currently tested in severe asthma: Anti - Immunoglobulin E (IgE) seems to have a good clinical effect while results on anti - Interleukin 5 (IL-5) are less promising and anti - tumor necrosis factor alpha (TNFα) treatment is currently being tested in controlled studies. Other steroid sparing drugs (cyclosporine, tacrolimus, methotrexate, gold) have been used but results are unsatisfactory and side-effects are notable so steroids remain the cornerstone of severe asthma treatment. The addition of macrolides is beneficial in many cases and this is in step with the evidence of chronic chlamydia infection in severe asthma. Although there are case reports supporting the use of Immunoglobulin G (IgG), there are no controlled studies supporting this type of treatment. In this report, the authors review the various issues of guideline based therapy but also new approaches that include anti-IgE antibodies, anti-cytokines (anti-IL-5, anti-IL9, anti-TNF).
Keywords: Severe asthma, management, ICS, LABA, leukotriene antagonists, anti-IgE, anti-TNFα
Current Medicinal Chemistry
Title: Evaluation and Management of Severe Asthma
Volume: 14 Issue: 9
Author(s): Mina Gaga, Eleftherios Zervas, Spiros Grivas, Mario Castro and Pascal Chanez
Affiliation:
Keywords: Severe asthma, management, ICS, LABA, leukotriene antagonists, anti-IgE, anti-TNFα
Abstract: Severe and difficult-to-treat asthma patients have impaired health status and account for over half of the cost of the disease and probably all of its mortality. Guideline-based treatment for these refractory asthma patients includes high doses of inhaled steroids and long acting beta2-agonists (LABA) as well as additional medication such as theophylline, oral steroids and leukotriene-antagonists. However, management regimens are rarely successful in these patients, the treating physicians are often at a loss and there are still many areas of uncertainty regarding steroid-responsiveness, safety issues and maximal dosing of inhaled corticosteroids (ICS) and bronchodilators and possible differences between ICS preparations. Furthermore, there are many other classes of medication that have been or are currently tested in severe asthma: Anti - Immunoglobulin E (IgE) seems to have a good clinical effect while results on anti - Interleukin 5 (IL-5) are less promising and anti - tumor necrosis factor alpha (TNFα) treatment is currently being tested in controlled studies. Other steroid sparing drugs (cyclosporine, tacrolimus, methotrexate, gold) have been used but results are unsatisfactory and side-effects are notable so steroids remain the cornerstone of severe asthma treatment. The addition of macrolides is beneficial in many cases and this is in step with the evidence of chronic chlamydia infection in severe asthma. Although there are case reports supporting the use of Immunoglobulin G (IgG), there are no controlled studies supporting this type of treatment. In this report, the authors review the various issues of guideline based therapy but also new approaches that include anti-IgE antibodies, anti-cytokines (anti-IL-5, anti-IL9, anti-TNF).
Export Options
About this article
Cite this article as:
Gaga Mina, Zervas Eleftherios, Grivas Spiros, Castro Mario and Chanez Pascal, Evaluation and Management of Severe Asthma, Current Medicinal Chemistry 2007; 14 (9) . https://dx.doi.org/10.2174/092986707780362961
DOI https://dx.doi.org/10.2174/092986707780362961 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Progress in the Development of Adenosine Receptor Ligands as Antiinflammatory Drugs
Current Topics in Medicinal Chemistry Nanomaterials as Emerging Environmental Threats
Current Chemical Biology Neuropeptides as Therapeutic Approach to Autoimmune Diseases
Current Pharmaceutical Design Editorial [Hot topic: Novel Approaches to Pharmacogenomic Investigations (Executive Editor: Kelan G. Tantisira)]
Current Pharmaceutical Design p53 Peptide Prevents LITAF-Induced TNF-Alpha-Mediated Mouse Lung Lesions and Endotoxic Shock
Current Molecular Medicine Immunomodulation Mechanism of Antidepressants: Interactions between Serotonin/Norepinephrine Balance and Th1/Th2 Balance
Current Neuropharmacology Immunoregulatory Impact of Food Antioxidants
Current Pharmaceutical Design Pulmonary Rehabilitation as Evaluated by Clinical Trials: An Overview
Reviews on Recent Clinical Trials Potential Strategies for Minimizing Mechanism-Based Inhibition of Cytochrome P450 3A4
Current Pharmaceutical Design Sleep Disturbances Due to Pulmonary Medications
Current Respiratory Medicine Reviews New Strategies and Biological Agents in the Treatment of Autoimmune Inflammatory Diseases. Progress and Challenges
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Intestinal Permeability in Non-alcoholic Fatty LIVER Disease: The Gut-liver Axis
Reviews on Recent Clinical Trials On the Cellular and Molecular Regulatory Transcriptional Mechanisms and Responsive Putative Pathways to Inflammatory Oxidative Stress Revisited: Current Immunological Breakthroughs and Views at a Glance
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Vaccines for Patients with COPD
Recent Patents on Inflammation & Allergy Drug Discovery Progress on the Screening and Analysis of Bioactive Compounds in Traditional Chinese Medicines by Biological Fingerprinting Analysis
Combinatorial Chemistry & High Throughput Screening Recent Patents on Electrospun Biomedical Nanostructures: An Overview
Recent Patents on Biomedical Engineering (Discontinued) Impact of Inhaled Corticosteroids on the Natural History of Asthma in Children
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Airway Smooth Muscle Cell as Therapeutic Target of Inflammation
Current Medicinal Chemistry Biotherapy for Autoimmune Liver Diseases
Current Pharmaceutical Biotechnology Enhancement by Nanogold of the Efficacy of a Light-Activated Antimicrobial Coating
Current Nanoscience